Studies Reinvigorate RA Mucosal Origins Hypothesis Studies Reinvigorate RA Mucosal Origins Hypothesis
Two studies provide new evidence and new angles for research into determining the origins of rheumatoid arthritis and potential ways to prevent or treat the disease early.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Screening for depressive symptoms in patients with rheumatoid arthritis: relationship with pain severity, disease activity, and sleep quality - Azzam AI, Lamlom M, Khalifa AM.
Rheumatoid arthritis (RA) is an autoimmune systemic condition that primarily affects all synovial joints, eventually leading to deformity and clinical disability. Much progress has been made in the evaluation of inflammation and disease activity in recent ... (Source: SafetyLit)
Source: SafetyLit - November 2, 2022 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Momentum Builds for Microbiome as RA Trigger
(MedPage Today) -- Another study has suggested that a component of the gut microbiome may contribute to development of rheumatoid arthritis (RA) -- but now it's a different bug from those previously implicated in the condition.
In a series of... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 26, 2022 Category: Gastroenterology Source Type: news
New ACR/EULAR Guideline Expands RA Remission Definition
(MedPage Today) -- Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
The more relaxed criteria... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 25, 2022 Category: Rheumatology Source Type: news
One in Four Rheumatoid Arthritis Patients Has Osteoporosis
FRIDAY, Oct. 21, 2022 -- More than one-quarter of patients with rheumatoid arthritis (RA) have osteoporosis, according to a study published online Sept. 23 in Scientific Reports.
Samaneh Moshayedi, from Arak University of Medical Sciences in Iran,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2022 Category: Pharmaceuticals Source Type: news
Biomarkers May ID RA Patients With, Without Active Disease
THURSDAY, Oct. 20, 2022 -- Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values may differentiate between rheumatoid arthritis (RA) patients with and without active disease, according to a systematic review published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2022 Category: Pharmaceuticals Source Type: news
Does Rheumatoid Arthritis Get Its Start in the Gut?
(MedPage Today) -- Evidence that at least some forms of rheumatoid arthritis (RA) are connected to the intestinal microbiome continues to mount, with a new study showing that antibodies to a common intestinal bacterium appear elevated throughout... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 20, 2022 Category: Gastroenterology Source Type: news
Analysis Explores Efficacy of Combination Therapy in Preventing Progression of Rheumatoid Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - October 20, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
JAK Inhibitors Show No Excess CV Safety Signal JAK Inhibitors Show No Excess CV Safety Signal
Compared with adalimumab, JAK inhibitors presented no higher risk for major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 20, 2022 Category: Cardiology Tags: Rheumatology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Notes From Underground: Miners Face Increased Risk of Rheumatoid Arthritis
(MedPage Today) -- Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
Based on survey data from men ages 50 and older... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 17, 2022 Category: American Health Source Type: news
Study: Patient Reports Can Substitute for Objective Measures in RA Evaluation
(MedPage Today) -- A model incorporating rheumatoid arthritis (RA) patients' self-reports matched conventional physician-led evaluations of disease activity to an acceptable degree, researchers said.
"Machine learning" applied to data collected... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 13, 2022 Category: Rheumatology Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
